The US Food and Drug Administration (FDA) has found traces of a known carcinogen in some drugs known to treat heartburn, such as ranitidine, such as Zantac, according to Al Arabiya.
US healthcare company CVS said it would halt sales of ranitidine-containing Zantac.
This month, the US Food and Drug Administration announced the discovery of trace amounts of N-nitrosodimethylamine, a carcinogen, in some tablets of the drug Zantac. In the shortage of these drugs.
CVS said the sales suspension was a precaution as the US Food and Drug Administration continues to review whether low levels of ranitidine, the active ingredient in Zantac, may be dangerous to health. The patients.
Novartis's Sandoz unit announced the suspension of Zantac distribution in all its markets, including the United States and Canada, after drug regulators in the United States and Europe announced a review of drug safety.